Guideline Summary for Tonsillar Squamous Cell Carcinoma

Epidemiology & Prognostic Features

• Approximately 69‑75 % of tonsillar squamous cell carcinoma (TSCC) cases present with cervical lymph‑node metastasis, underscoring the disease’s high metastatic propensity. 1
• HPV‑positive TSCC (identified by p16 immunohistochemistry) is associated with superior overall and disease‑specific survival compared with HPV‑negative disease, although current guidelines recommend identical treatment intensity because de‑escalation remains investigational. 2
• In clinically node‑negative patients, occult cervical metastasis is found in about 23‑24 % of cases, supporting routine elective neck treatment. 3
• Roughly 50 % of patients with locally advanced TSCC experience disease recurrence after primary therapy, most recurrences occurring within the first two years. 4

Diagnostic Workup

• Flexible endoscopic examination of the oropharynx and bilateral neck is essential for assessing primary tumor extent and nodal involvement. 1
• Contrast‑enhanced CT or MRI should be performed to evaluate tumor depth, bone or soft‑tissue invasion, and regional nodal disease. 1
• p16 immunohistochemistry on biopsy specimens serves as a validated surrogate marker for HPV status and provides prognostic stratification. 2
• PD‑L1 testing (FDA‑approved immunohistochemistry) is required for patients with recurrent or metastatic disease to guide immunotherapy selection. 2
• Dihydropyrimidine dehydrogenase (DPD) testing must be completed before initiating 5‑fluorouracil‑based chemotherapy to prevent severe toxicity. 1

Early‑Stage Disease (T1‑T2, N0‑N1)

• Single‑modality treatment—either surgery or definitive radiotherapy—provides equivalent locoregional control and overall survival in early‑stage TSCC. 1
• Surgical management should consist of wide local excision with ≥5 mm margins plus elective ipsilateral selective neck dissection (levels I‑III) to address the 23‑24 % risk of occult metastasis. 3
• When radiotherapy is chosen, intensity‑modulated radiotherapy (IMRT) or volumetric‑modulated arc therapy (VMAT) delivering a total dose of 70 Gy is mandatory. 1

Locally Advanced Disease (T3‑T4 or N2‑N3)

• Primary surgery with en‑bloc resection of the tumor (including involved mandible or skin when necessary) followed by comprehensive ipsilateral neck dissection offers comparable survival to primary concurrent chemoradiotherapy. 1
• Post‑operative radiotherapy (58‑64 Gy) is indicated for pT3‑T4 disease, positive or close margins (≤5 mm), perineural invasion, lymphovascular invasion, >1 involved lymph node, or extracapsular extension. 4
• Post‑operative concurrent chemoradiotherapy (66 Gy plus high‑dose cisplatin) is required for R1 resections or extracapsular nodal extension, improving overall survival versus radiotherapy alone. 5
• The interval from surgery to the start of adjuvant radiotherapy/chemoradiotherapy should not exceed 6‑7 weeks, and the entire adjuvant sequence should be completed within 11 weeks to preserve locoregional control. 4
• Standard concurrent chemotherapy regimen: cisplatin 100 mg/m² on days 1, 22, and 43 administered with radiotherapy. 1
• For patients unsuitable for high‑dose cisplatin, alternatives include weekly cisplatin 40 mg/m², carboplatin + 5‑FU, cetuximab, or hyperfractionated/accelerated radiotherapy without chemotherapy. 5
• Primary concurrent chemoradiotherapy (70 Gy IMRT/VMAT plus cisplatin 100 mg/m² on days 1, 22, 43) is the standard organ‑preservation approach, offering survival outcomes equivalent to primary surgery. 1
• Adding hypoxic radiosensitizers to radiotherapy improves locoregional control and disease‑free survival compared with radiotherapy alone. 1
• Routine neck dissection is not required if a 12‑week post‑treatment FDG‑PET/CT shows no metabolic activity and nodes are of normal size. 1

Recurrent and Metastatic Disease

• Treatment selection is based on PD‑L1 expression, prior platinum exposure, and patient performance status. 4
• PD‑L1‑positive (CPS ≥ 1) tumors:
  
  • Pembrolizumab monotherapy is the preferred first‑line option for patients who do not require rapid tumor shrinkage. 5
  • Pembrolizumab combined with platinum‑based chemotherapy and 5‑FU is recommended when a swift response is clinically necessary. 3
• PD‑L1‑negative tumors: The EXTREME regimen (platinum + 5‑FU + cetuximab) remains the standard first‑line therapy. 3
• After progression on platinum‑based therapy within 6 months, nivolumab is the preferred second‑line agent, providing a median overall survival of 7.5 months versus 5.1 months with standard chemotherapy. 3
• Alternative second‑line options include cetuximab (median OS 5.2‑6.1 months), taxane‑based regimens (with or without cetuximab or methotrexate), or the TPE combination (cisplatin + docetaxel + cetuximab), though the latter lack randomized trial evidence. 3
• Patients with isolated locoregional recurrence should be evaluated at a tertiary center for possible salvage surgery or re‑irradiation in highly selected cases. 4
• Oligometastatic disease (≤ 2 distant sites) may be considered for curative‑intent local or regional treatment after an adequate systemic response. 4

Multidisciplinary Care & Facility Requirements

• All management decisions must be reviewed by a multidisciplinary head‑and‑neck tumor board comprising surgeons, radiation oncologists, medical oncologists, pathologists, radiologists, and supportive‑care specialists (speech/swallowing, nutrition, psychology). 1
• Patients should be treated at high‑volume centers with dedicated head‑and‑neck oncology programs to achieve optimal outcomes. 1

All facts above are derived from peer‑reviewed guideline sources and are presented with their corresponding citation identifiers.